Mercer Global Advisors
RNA

Mercer Global Advisors’s Atrium Therapeutics RNA Stock Holding History

Mercer Global Advisors’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Buy
+7,891
New +$103K ﹤0.01% 3801

Other funds holding RNA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $144M AUM 26.42% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return

Mercer Global Advisors's RNA Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 7,891 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #3801 among its holdings.

139 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Mercer Global Advisors held 7,891 shares of Atrium Therapeutics worth $106K as of Q2 2026.
  • Atrium Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3801 holding.
  • 139 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.